Next-Generation Cancer Biomarkers: Extracellular Vesicle DNA as a Circulating Surrogate of Tumor DNA.
EV-DNA
cancer
circulating biomarker
exosomes
extracellular vesicles
liquid biopsy
microvesicles
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
10
2020
accepted:
17
12
2020
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
20
2
2021
Statut:
epublish
Résumé
Extracellular vesicles (EVs) are produced by healthy tissues and tumor cells and are released in various bodily fluids, including blood. They are limited by bilayer phospholipidic membranes, and they carry a rich content in biomolecules. Their release cleanses the cells of their waste or serves as functional local and distant cell-cell communication and molecular exchange particles. This rich and heterogeneous content has been given intense attention in cancer physiopathology because EVs support cancer control and progression. Because of their specific active cargo, they are being evaluated as carriers of liquid biopsy biomarkers. Compared to soluble circulating biomarkers, their complexity might provide rich information on tumor and metastases status. Thanks to the acquired genomic changes commonly observed in oncogenic processes, double-stranded DNA (dsDNA) in EVs might be the latest most promising biomarker of tumor presence and complexity. This review will focus on the recent knowledge on the DNA inclusion in vesicles, the technical aspects of EV-DNA detection and quantification, and the use of EV-DNA as a clinical biomarker.
Identifiants
pubmed: 33604335
doi: 10.3389/fcell.2020.622048
pmc: PMC7884755
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
622048Informations de copyright
Copyright © 2021 Amintas, Vendrely, Dupin, Buscail, Laurent, Bournet, Merlio, Bedel, Moreau-Gaudry, Boutin, Dabernat and Buscail.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Extracell Vesicles. 2018 Aug 07;7(1):1505403
pubmed: 30108686
Ann Oncol. 2017 Apr 1;28(4):741-747
pubmed: 28104621
Biomedicines. 2020 May 22;8(5):
pubmed: 32455948
BMC Cancer. 2016 Sep 23;16(1):753
pubmed: 27662833
Inflammation. 2020 Dec;43(6):2021-2032
pubmed: 32830308
Kidney Int. 2010 Jul;78(2):191-9
pubmed: 20428099
Mol Cancer. 2018 Aug 23;17(1):128
pubmed: 30139385
Sci Rep. 2018 Oct 2;8(1):14707
pubmed: 30279572
Trends Cell Biol. 1995 Jan;5(1):21-6
pubmed: 14731429
Front Oncol. 2019 Sep 25;9:931
pubmed: 31608233
Epigenomics. 2015;7(6):1003-15
pubmed: 26479312
Cell Rep. 2019 Apr 16;27(3):940-954.e6
pubmed: 30956133
Ann Oncol. 2018 Mar 1;29(3):700-706
pubmed: 29216356
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207
pubmed: 28874546
Trends Cell Biol. 2009 Feb;19(2):43-51
pubmed: 19144520
Cancer Sci. 2018 Aug;109(8):2364-2374
pubmed: 29908100
Sci Rep. 2017 Aug 15;7(1):8202
pubmed: 28811610
Prostate. 2014 Oct;74(14):1379-90
pubmed: 25111183
Transl Oncol. 2019 Nov;12(11):1395-1403
pubmed: 31400579
Ann Oncol. 2016 Apr;27(4):635-41
pubmed: 26681674
Nat Commun. 2017 May 16;8:15287
pubmed: 28508895
Cell Commun Signal. 2017 Apr 4;15(1):14
pubmed: 28376875
Nat Cell Biol. 2018 Mar;20(3):332-343
pubmed: 29459780
J Proteome Res. 2018 Oct 5;17(10):3599-3605
pubmed: 30192545
Cell. 2019 Apr 4;177(2):428-445.e18
pubmed: 30951670
Cell Res. 2014 Jun;24(6):766-9
pubmed: 24710597
Nature. 2017 Aug 24;548(7668):466-470
pubmed: 28759889
J Biol Chem. 2014 Feb 14;289(7):3869-75
pubmed: 24398677
Oncotarget. 2017 Jan 3;8(1):1416-1428
pubmed: 27902458
Cancers (Basel). 2019 Oct 26;11(11):
pubmed: 31717747
J Clin Med. 2020 May 12;9(5):
pubmed: 32408624
Nanomedicine. 2018 Apr;14(3):875-882
pubmed: 29288729
PLoS One. 2017 Aug 29;12(8):e0183915
pubmed: 28850588
J Clin Invest. 2016 Apr 1;126(4):1208-15
pubmed: 27035812
Clin Cancer Res. 2018 Jun 15;24(12):2944-2950
pubmed: 29535126
Cancer Biol Ther. 2017 Mar 4;18(3):158-165
pubmed: 28121262
Curr Med Chem. 2019;26(8):1328-1350
pubmed: 28933282
Sci Rep. 2020 Jan 23;10(1):1039
pubmed: 31974468
Biomed Microdevices. 2020 Mar 11;22(2):23
pubmed: 32162067
Oncoimmunology. 2020 Jun 16;9(1):1777624
pubmed: 32934881
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9066-E9075
pubmed: 29073103
Biochem Biophys Res Commun. 2014 Aug 22;451(2):295-301
pubmed: 25086355
Clin Transl Gastroenterol. 2016 Jul 21;7(7):e184
pubmed: 27441821
J Extracell Vesicles. 2019 Aug 27;8(1):1656993
pubmed: 31497265
Nat Commun. 2011 Feb 01;2:180
pubmed: 21285958
Transl Lung Cancer Res. 2019 Dec;8(6):1051-1060
pubmed: 32010582
PLoS One. 2016 Sep 29;11(9):e0163665
pubmed: 27684368
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33007940
Mutagenesis. 2011 Jan;26(1):125-32
pubmed: 21164193
Theranostics. 2020 Feb 19;10(8):3684-3707
pubmed: 32206116
Cells. 2020 Aug 25;9(9):
pubmed: 32854228
J Vis Exp. 2018 Apr 13;(134):
pubmed: 29708539
Sci Rep. 2020 Sep 25;10(1):15745
pubmed: 32978468
J Neural Transm (Vienna). 2010 Jan;117(1):1-4
pubmed: 19680595
Int J Mol Sci. 2020 Sep 04;21(18):
pubmed: 32899828
Biochem Cell Biol. 1992 Mar-Apr;70(3-4):179-90
pubmed: 1515120
Sci Adv. 2019 Nov 20;5(11):eaax8849
pubmed: 31799396
Gastroenterology. 2019 Jan;156(1):108-118.e4
pubmed: 30240661